Xerox Corporation

University of Massachusetts

Zhaoyang Ou

Zhen Lai

Chieh-Min Cheng

Christopher David Blair

Shigang S Qiu

Kimberly D Nosella

David R Kurceba

Deniz Elizabeth Civay

Murugappan Muthukumar

Dennis A Mattison, Jr

Daryl Walter Vanbesien

Robert D Bayley

Santiago Faucher

Allan K Chen

Steven M Malachowski

John Abate

Rashid Mahmood

Philip J Dale

Ryan Accetta

Phil Dale

Dennis A Mattison

Ryan J Accetta

Described herein are methods of inhibiting or reversing the progression of presbyopia in an eye by administering a &#x3b2;-crystallin electrostatic interaction inhibitor. Presbyopia is caused by aggregation of the soluble crystalline lens proteins called the crystallins, particularly &#x3b2;-crystallin. It has been found that the aggregation of &#x3b2;-crystallin is an electrostatic phenomenon and that electrostatic interaction inhibitors can be employed to prevent the formation of &#x3b2;-crystallin aggregates as well as to deaggregate already formed aggregates.

Methods of inhibiting presbyopia

A washing process using one or more ionic liquids (ILs) as a washing aid agent for toners, including toners produced using such ILs, such as, low melt toners, is provided. ILs are environmentally sound, green solvents that act to swell toner particle surfaces so that surface absorbed and adsorbed pollutants, such as, surfactants and other manufacturing reactants, can be effectively removed. The resulting toners have good charging, charge maintenance and RH sensitivity.

Toner wash comprising ionic liquid

A process for making toner particles is provided. In embodiments, a suitable process includes adding a washing aid agent to toner particles at the time of washing the toner particles prior to their drying and recover. The washing aid agent assist in the removal of ionic species, including surfactants and ions that are part of the emulsion aggregation process, from the resulting toner particles. Utilization of the washing aid agent produces toner particles having improved charging characteristics.

Toner processes utilizing washing aid

Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a &#x3b2;-crystallin electrostatic interaction inhibitor. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins, particularly &#x3b2;-crystallin. It has been found that the aggregation of &#x3b2;-crystallin is an electrostatic phenomenon and that electrostatic interaction inhibitors can be employed to prevent the formation of &#x3b2;-crystallin aggregates as well as to deaggregate already formed aggregates.

Methods of inhibiting cataracts and presbyopia

A process and system for making a resin emulsion suitable for use in forming toner particles including a silicone free anti-foam agent to control foam during formation of a polyester dispersion.

Efficient solvent-based phase inversion emulsification process with defoamer

A toner composition that includes at least one low molecular weight amorphous polyester resin, at least one high molecular weight amorphous polyester resin, at least one crystalline polyester resin, at least one wax, at least one biocide and at least one colorant, and wherein the toner composition has a minimum fusing temperature of from about 100&#xb0; C. to about 125&#xb0; C.

Emulsion aggregation toner composition

A process for making a latex emulsion suitable for use in a toner composition includes contacting at least one crystalline polyester resin with an organic solvent to form a resin mixture, adding a neutralizing agent, and deionized water to the resin mixture, removing the solvent from the formed latex, and continuously recovering latex particles.

Processes for producing polyester latexes via single-solvent-based emulsification

A process for making toner particles is provided. In embodiments, a suitable process includes adding a defoamer to an emulsion utilized to form toner particles. Utilization of the defoamer allows for a reduction in the overall aggregation/coalescence cycle time and slurry viscosity, while producing a toner with improved GSDs, low coarse and target circularities.

Toner processes utilizing a defoamer as a coalescence aid for continuous and batch emulsion aggregation

A method for making a pharmaceutical by emulsion aggregation, the method including emulsifying a first pharmaceutical agent and a biodegradable resin to form a primary emulsion of pre-aggregated particles in a slurry; aggregating the pre-aggregated particles to form aggregated pharmaceutical particles in the slurry; and isolating the pharmaceutical particles. The method may be used to make time-released, multi-formulation, and inhalable pharmaceuticals.

Methods for preparing pharmaceuticals by emulsion aggregation processes

A process for making particles is provided. In embodiments, a suitable process includes adding a rheology modifier to an emulsion utilized to form toner particles. The rheology modifier permits the use of a higher solid content in the emulsion, with a resulting higher yield of toner particles, without requiring the use of powerful mixing equipment.

Toner process including modifying rheology

A process for making a latex emulsion suitable for use in a toner composition includes contacting at least one amorphous polyester resin with an organic solvent to form a resin mixture, adding a neutralizing agent, and deionized water to the resin mixture, removing the solvent from the formed latex, separating the solvent from water, and recycling the solvent from the resin mixture for utilization in a subsequent phase inversion emulsion process.

Growing community of inventors

Webster, NY, United States of America

Zhaoyang Ou